Your session is about to expire
← Back to Search
Anti-metabolites
Integrative Chemotherapy for Advanced Pancreatic Cancer
Phase 2
Waitlist Available
Led By Ben Chue, MD
Research Sponsored by Seattle Cancer Treatment and Wellness Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
No other serious concomitant illness
Age ≤ 65
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Study Summary
This trial is testing a chemotherapy drug combination and dosing to see if it is effective in treating advanced pancreatic cancer.
Who is the study for?
Adults under 66 with advanced pancreatic cancer that can't be removed by surgery or treated with radiation, and who didn't respond to initial chemotherapy. They must have recovered from prior treatments, not have serious illnesses or certain allergies, and agree to use contraception if they can bear children.Check my eligibility
What is being tested?
The trial is testing a weekly combination of chemotherapy drugs (paclitaxel, oxaliplatin, leucovorin, and 5-fluorouracil) as second or third-line treatment for patients whose pancreatic cancer has worsened after first-line gemcitabine therapy.See study design
What are the potential side effects?
Possible side effects include fatigue, nausea, vomiting, low blood cell counts increasing infection risk; nerve damage causing numbness or pain; allergic reactions; kidney issues reflected in creatinine levels; and potential harm to an unborn child.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I do not have any serious illnesses besides my current condition.
Select...
I am 65 years old or younger.
Select...
My pancreatic cancer cannot be treated with surgery, radiation, or has not responded to gemcitabine chemotherapy.
Select...
I can take care of myself but might not be able to do heavy physical work.
Select...
I am 65 years old or younger.
Select...
My cancer has not spread to my brain.
Select...
I am older than 18 years.
Select...
I am not pregnant or breastfeeding and am using birth control.
Select...
I do not have severe numbness or pain in my hands or feet.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Clinical response rate (PS improvement by ECOG score, analgesic dose reduction)
Median survival
Overall survival
+3 moreSecondary outcome measures
Tolerance and Safety NCI-CTC version 2
Find a Location
Who is running the clinical trial?
Seattle Cancer Treatment and Wellness CenterLead Sponsor
Ben Chue, MDPrincipal InvestigatorSeattle Cancer Treatment and Wellness Center
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have not had surgery in the last 2 weeks.I do not have any serious illnesses besides my current condition.Your absolute neutrophil count is higher than 1500.Your creatinine level is not higher than 2.0.I am 65 years old or younger.I have not had radiotherapy in the last 6 weeks.My pancreatic cancer cannot be treated with surgery, radiation, or has not responded to gemcitabine chemotherapy.I have received Oxaliplatin, 5-FU, Tarceva, or Erbitux for advanced disease.Your platelet count is higher than 75,000.I can take care of myself but might not be able to do heavy physical work.I have fully recovered from my previous treatments.I am 65 years old or younger.My cancer has not spread to my brain.My gender does not affect my eligibility for this study.I am older than 18 years.I do not have any uncontrolled serious illnesses.I need considerable assistance and am unable to do any work.I am not pregnant or breastfeeding and am using birth control.I do not have severe numbness or pain in my hands or feet.
Research Study Groups:
This trial has the following groups:Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Has this therapy obtained governmental authorization?
"Considering the Phase 2 trial design, with supporting evidence for safety but not efficacy, our team assigned this treatment a score of 2."
Answered by AI
Are there any age restrictions for applicants to this clinical experiment?
"Volunteers for this experiment must be between 18 and 65 years of age."
Answered by AI
Are there any opportunities for individuals to join this clinical investigation?
"According to the details published on clinicaltrials.gov, this study is no longer enrolling participants as it was last updated in May 2007. Despite not actively recruiting any more candidates, there are still 576 other trials that require volunteers."
Answered by AI
Am I able to join this medical experiment?
"This medical study is recruiting 80 individuals, aged 18 to 65, who have been diagnosed with pancreatic cancer. To be eligible for consideration, they must not be able to undergo surgery or radiation therapy and cannot receive either oxaliplatin or 5-fluorouracil as part of their treatment plan. The subset analysis will separately evaluate those patients receiving Tarceva and/or Erbitux."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger